<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590601</url>
  </required_header>
  <id_info>
    <org_study_id>MP-33-2015-1874 (MP)</org_study_id>
    <nct_id>NCT02590601</nct_id>
  </id_info>
  <brief_title>Bromocriptine in the Treatment of Peripartum Cardiomyopathy</brief_title>
  <acronym>BRO-HF</acronym>
  <official_title>Bromocriptine in the Treatment of Peripartum Cardiomyopathy, A Bayesian Randomized Registry Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cardiovascular Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripartum cardiomyopathy (PPCM) is a rare, but significant heart disease affecting young
      women in the puerperal period. Thus far, no specific treatment has been approved to treat
      this disease. PPCM has a wide spectrum of clinical manifestations ranging from mild heart
      failure to severe cardiomyopathy, cardiogenic shock and death. A significant proportion of
      survivors have persistent chronic heart failure leading to disabling symptoms and decreased
      quality of life.

      Animal studies have suggested that prolactin is central to the development of PPCM. Prolactin
      has pro-inflammatory and anti-angiogenic effects that may promote PPCM. Bromocriptine, a
      central dopamine agonist known to decrease prolactin levels, might thwart its deleterious
      effects in women suffering from PPCM. Following this rationale, bromocriptine should improve
      myocardial function in women suffering from PPCM and thus, improve cardiovascular outcomes
      and healthcare outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>1 year</time_frame>
    <description>MACE : A compose of death from cardiovascular causes, aborted sudden death, heart transplantation, mechanical circulatory support or hospitalization for cardiovascular causes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular causes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) recovery</measure>
    <time_frame>6 months</time_frame>
    <description>Recovery defined as : (proportion of patients with LVEF ≥ 54%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of arrythmias</measure>
    <time_frame>1 year</time_frame>
    <description>Arrhythmia : Number of participants with sustained ventricular tachycardia, ventricular fibrillation or new onset atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all-cause hospitalisation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL) with the Kansas City Cardiomyopathy questionnaire (KCCQ)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL) with the World Health Organization (WHO) quality of life questionnaire (WHOQOL-BREF)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart transplantation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical circulatory support</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisation for cardiovascular causes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety adverse events: Combined occurence of venous thromboembolic disease, cardiac thrombus with embolic manifestation, myocardial infarction or cerebrovascular accident.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Peripartum Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Bromocriptine + Guideline-driven medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.
Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guideline-driven medical therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromocriptine</intervention_name>
    <arm_group_label>Bromocriptine + Guideline-driven medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Guideline-driven medical therapy (GDMT)</intervention_name>
    <arm_group_label>Bromocriptine + Guideline-driven medical therapy</arm_group_label>
    <arm_group_label>Guideline-driven medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years;

          2. Peripartum cardiomyopathy defined by the following criteria:

               -  Development of heart failure in the last month of pregnancy or within 5 months of
                  delivery;

               -  Absence of an identifiable alternative cause of heart failure;

               -  Absence of recognizable heart disease prior to the last month of pregnancy;

               -  Left ventricular systolic dysfunction demonstrated by classic echocardiographic
                  criteria, such as depressed ejection fraction;

          3. Recent onset of PPCM ( 1 month);

          4. Written informed consent.

        Exclusion Criteria:

          1. Hypersensitivity or contraindication to bromocriptine;

          2. Patients already taking bromocriptine for PPCM or for another indication;

          3. Cardiogenic shock before enrolment;

          4. Survival expected to be less than 1 year due to non-cardiovascular causes (eg.
             cancer);

          5. Participation to another investigational drug or investigational device study within
             30 days prior to randomization (participation to registries is allowed);

          6. Patients who in the opinion of the investigator will not comply with specified drugs,
             or follow-up evaluation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Avram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maxime Tremblay-Gravel, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume Marquis-Gravel, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Desplantie, MD CM, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anique Ducharme, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Jolicoeur, MD, M.Sc., MHS</last_name>
    <phone>514-376-3330</phone>
    <phone_ext>3685</phone_ext>
    <email>marc.jolicoeur@icm-mhi.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Gabrielle Lessard, RN, B.Sc.</last_name>
    <phone>Phone: 514-376-3330</phone>
    <phone_ext>2094/2</phone_ext>
    <email>marie-gabrielle.lessard@icm-mhi.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Monteal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Jolicoeur, MD, M.Sc., MHS</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3685</phone_ext>
      <email>marc.jolicoeur@icm-mhi.org</email>
    </contact>
    <contact_backup>
      <last_name>Luc Harvey, RN</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>2776</phone_ext>
      <email>luc.harvey@icm-mhi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anique Ducharme, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.bro-hf.com</url>
    <description>Website of our project.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>September 2, 2017</last_update_submitted>
  <last_update_submitted_qc>September 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Marc Jolicoeur</investigator_full_name>
    <investigator_title>Lead investigator</investigator_title>
  </responsible_party>
  <keyword>PPCM</keyword>
  <keyword>Bromocriptine</keyword>
  <keyword>Peripartum cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromocriptine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

